{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T06:47:14Z","timestamp":1756190834250,"version":"3.37.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,5,17]],"date-time":"2018-05-17T00:00:00Z","timestamp":1526515200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s00296-018-4054-9","type":"journal-article","created":{"date-parts":[[2018,5,17]],"date-time":"2018-05-17T09:49:52Z","timestamp":1526550592000},"page":"1301-1306","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Improvement of neurological and ocular symptoms of Beh\u00e7et\u2019s disease after the introduction of infliximab"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6281-5705","authenticated-orcid":false,"given":"Marko","family":"Bare\u0161i\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3074-1646","authenticated-orcid":false,"given":"Mirna","family":"Reihl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3360-1748","authenticated-orcid":false,"given":"Mario","family":"Habek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7561-8858","authenticated-orcid":false,"given":"Nenad","family":"Vukojevi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Branimir","family":"Ani\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,17]]},"reference":[{"issue":"6","key":"4054_CR1","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s11926-010-0132-z","volume":"12","author":"Y Yazici","year":"2010","unstructured":"Yazici Y, Yurdakul S, Yazici H (2010) Beh\u00e7et\u2019s syndrome. Curr Rheumatol Rep 12(6):429\u2013435","journal-title":"Curr Rheumatol Rep"},{"issue":"5 Suppl 42","key":"4054_CR2","first-page":"S125","volume":"24","author":"NG Papoutsis","year":"2006","unstructured":"Papoutsis NG, Abdel-Naser MB, Altenburg A, Orawa H, K\u00f6tter I, Krause L et al (2006) Prevalence of Adamantiades-Beh\u00e7et\u2019s disease in Germany and the municipality of Berlin: results of a nationwide survey. Clin Exp Rheumatol 24(5 Suppl 42):S125","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"4054_CR3","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s10067-010-1430-6","volume":"29","author":"F Davatchi","year":"2010","unstructured":"Davatchi F, Shahram F, Chams-Davatchi C, Shams H, Nadji A, Akhlaghi M et al (2010) Behcet\u2019s disease: from East to West. Clin Rheumatol 29(8):823\u2013833","journal-title":"Clin Rheumatol"},{"issue":"12","key":"4054_CR4","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1002\/art.24149","volume":"58","author":"A Mahr","year":"2008","unstructured":"Mahr A, Belarbi L, Wechsler B, Jeanneret D, Dhote R, Fain O et al (2008) Population-based prevalence study of Beh\u00e7et\u2019s disease: differences by ethnic origin and low variation by age at immigration. Arthritis Rheum 58(12):3951\u20133959","journal-title":"Arthritis Rheum"},{"issue":"10","key":"4054_CR5","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1046\/j.1365-4362.2003.01893.x","volume":"42","author":"G Azizlerli","year":"2003","unstructured":"Azizlerli G, K\u00f6se AA, Sarica R, G\u00fcl A, Tutkun IT, Kula\u00e7 M et al (2003) Prevalence of Beh\u00e7et\u2019s disease in Istanbul, Turkey. Int J Dermatol 42(10):803\u2013806","journal-title":"Int J Dermatol"},{"key":"4054_CR6","unstructured":"Seaman G, Pearce RA (1997) Behcet\u2019s disease manifestation in a population drawn from the UK Behcet\u2019s syndrome society. In: Hamza M (ed). Behcet\u2019s Disease, Pub Adhoua, Tunisia. pp 196\u2013199"},{"key":"4054_CR7","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/607921","author":"F Davatchi","year":"2012","unstructured":"Davatchi F (2012) Diagnosis\/classification criteria for Behcet\u2019s disease. Pathol Res Int. \n                    https:\/\/doi.org\/10.1155\/2012\/607921","journal-title":"Pathol Res Int"},{"issue":"8697","key":"4054_CR8","first-page":"1078","volume":"335","author":"International Study Group for Beh\u00e7et","year":"1990","unstructured":"International Study Group for Beh\u00e7et\u2019s Disease (1990) Criteria for diagnosis of Beh\u00e7et\u2019s disease. Lancet Lond Engl 335(8697):1078\u20131080","journal-title":"Lancet Lond Engl"},{"key":"4054_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213225","author":"G Hatemi","year":"2018","unstructured":"Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F et al (2018) 2018 update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome. Ann Rheum Dis. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2018-213225","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"4054_CR10","first-page":"1544","volume":"20","author":"JL Mege","year":"1993","unstructured":"Mege JL, Dilsen N, Sanguedolce V, Gul A, Bongrand P, Roux H et al (1993) Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Beh\u00e7et\u2019s disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 20(9):1544\u20131549","journal-title":"J Rheumatol"},{"issue":"5","key":"4054_CR11","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.cyto.2003.09.003","volume":"24","author":"M Misumi","year":"2003","unstructured":"Misumi M, Hagiwara E, Takeno M, Takeda Y, Inoue Y, Tsuji T et al (2003) Cytokine production profile in patients with Behcet\u2019s disease treated with infliximab. Cytokine 24(5):210\u2013218","journal-title":"Cytokine"},{"issue":"2","key":"4054_CR12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.clim.2011.01.014","volume":"139","author":"AMA El-Asrar","year":"2011","unstructured":"El-Asrar AMA, Struyf S, Kangave D, Al-Obeidan SS, Opdenakker G, Geboes K et al (2011) Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. Clin Immunol Orlando Fla 139(2):177\u2013184","journal-title":"Clin Immunol Orlando Fla"},{"key":"4054_CR13","first-page":"663","volume-title":"Ocular infection and immunity","author":"M Mochizuki","year":"1996","unstructured":"Mochizuki M, Akduman L, Nussenblatt R. Behc\u00b8et\u2019s disease. In: Pepose JS, Holland GN, Wilhelmus KR (eds). Ocular infection and immunity. St Louis: Mosby. 1996;663\u2013675"},{"issue":"5","key":"4054_CR14","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00417-009-1234-z","volume":"248","author":"T Kaburaki","year":"2010","unstructured":"Kaburaki T, Araki F, Takamoto M, Okinaga K, Yoshida A, Numaga J et al (2010) Best-corrected visual acuity and frequency of ocular attacks during the initial 10\u00a0years in patients with Beh\u00e7et\u2019s disease. Graefes Arch Clin Exp Ophthalmol 248(5):709\u2013714","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"4054_CR15","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/MAJ.0b013e3180318fbc","volume":"27","author":"PG Theodossiadis","year":"2007","unstructured":"Theodossiadis PG, Markomichelakis NN, Sfikakis PP (2007) Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina Phila Pa 27(4):399\u2013413","journal-title":"Retina Phila Pa"},{"issue":"2","key":"4054_CR16","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1517\/14728214.2011.537824","volume":"16","author":"T Larson","year":"2011","unstructured":"Larson T, Nussenblatt RB, Sen HN (2011) Emerging drugs for uveitis. Expert Opin Emerg Drugs 16(2):309\u2013322","journal-title":"Expert Opin Emerg Drugs"},{"key":"4054_CR17","first-page":"5","volume":"6","author":"F Cantini","year":"2012","unstructured":"Cantini F, Niccoli L, Nannini C, Kaloudi O, Cassar\u00e0 E, Susini M, Lenzetti I (2012) Efficacy of infliximab in refractory Beh\u00e7et\u2019s disease-associated and idiopathic posterior segmentuveitis: a prospective, follow-up study of 50 patients. Biologics 6:5\u201312","journal-title":"Biologics"},{"issue":"5","key":"4054_CR18","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1001\/archophthalmol.2011.2698","volume":"130","author":"AA Okada","year":"2012","unstructured":"Okada AA, Goto H, Ohno S, Mochizuki M, Ocular Beh\u00e7et\u2019s Disease Research Group Of Japan (2012) Multicenter study of infliximab for refractory uveoretinitis in Beh\u00e7et disease. Arch Ophthalmol Chic Ill 1960 130(5):592\u2013598","journal-title":"Arch Ophthalmol Chic Ill"},{"issue":"6","key":"4054_CR19","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3109\/09273948.2013.779727","volume":"21","author":"S Al Rashidi","year":"2013","unstructured":"Al Rashidi S, Al Fawaz A, Kangave D, Abu El-Asrar AM (2013) Long-term clinical outcomes in patients with refractory uveitis associated with Beh\u00e7et disease treated with infliximab. Ocul Immunol Inflamm 21(6):468\u2013474","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"4054_CR20","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.ajo.2012.03.035","volume":"154","author":"N Markomichelakis","year":"2012","unstructured":"Markomichelakis N, Delicha E, Masselos S, Sfikakis PP (2012) Intravitreal infliximab for sight-threatening relapsing uveitis in Beh\u00e7et disease: a pilot study in 15 patients. Am J Ophthalmol 154(3):534\u2013541.e1","journal-title":"Am J Ophthalmol"},{"key":"4054_CR21","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1093\/brain\/122.11.2171","volume":"122","author":"G Akman-Demir","year":"1999","unstructured":"Akman-Demir G, Serdaroglu P, Tas\u00e7i B (1999) Clinical patterns of neurological involvement in Beh\u00e7et\u2019s disease: evaluation of 200 patients. The Neuro-Beh\u00e7et Study Group. Brain 122:2171\u20132182","journal-title":"Brain"},{"issue":"12","key":"4054_CR22","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1136\/ard.2007.080432","volume":"67","author":"G Hatemi","year":"2008","unstructured":"Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A et al (2008) EULAR recommendations for the management of Beh\u00e7et disease. Ann Rheum Dis 67(12):1656\u20131662","journal-title":"Ann Rheum Dis"},{"key":"4054_CR23","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003550","author":"AC Desbois","year":"2016","unstructured":"Desbois AC, Addimanda O, Bertrand A, Deroux A, P\u00e9rard L, Depaz R et al (2016) Efficacy of anti-TNF\u03b1 in severe and refractory neuro-Behcet Disease. Medicine (Baltimore). \n                    https:\/\/doi.org\/10.1097\/MD.0000000000003550","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"4054_CR24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.semarthrit.2010.09.002","volume":"41","author":"A Arida","year":"2011","unstructured":"Arida A, Fragiadaki K, Giavri E, Sfikakis PP (2011) Anti-TNF agents for Beh\u00e7et\u2019s disease: analysis of published data on 369 patients. Semin Arthritis Rheum 41(1):61\u201370","journal-title":"Semin Arthritis Rheum"},{"key":"4054_CR25","first-page":"133","volume":"31","author":"FS Neves","year":"2013","unstructured":"Neves FS, Ferreira RM, Pereira IA, Zimmermann AF, Lin K (2013) Neuro-Beh\u00e7et\u2019s disease, its mimickers and anti-TNF therapy: a case-based review. Clin Exp Rheumatol. 31:133\u2013140","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"4054_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.cyto.2008.11.002","volume":"45","author":"A Fromont","year":"2009","unstructured":"Fromont A, De Seze J, Fleury MC, Maillefert JF, Moreau T (2009) Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. Cytokine 45(2):55\u201357","journal-title":"Cytokine"},{"issue":"6","key":"4054_CR27","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.semarthrit.2007.08.003","volume":"37","author":"MF Costa","year":"2008","unstructured":"Costa MF, Said NR, Zimmermann B (2008) Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 37(6):381\u2013387","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"4054_CR28","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/QCO.0b013e32832dda55","volume":"22","author":"RS Wallis","year":"2009","unstructured":"Wallis RS (2009) Infectious complications of tumor necrosis factor blockade. Curr Opin Infect Dis 22(4):403\u2013409","journal-title":"Curr Opin Infect Dis"},{"issue":"3","key":"4054_CR29","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/j.1756-185X.2009.01420.x","volume":"12","author":"GM Abalos-Medina","year":"2009","unstructured":"Abalos-Medina GM, S\u00e1nchez-Cano D, Ruiz-Villaverde G, Ruiz-Villaverde R, Quirosa Flores S, Raya Alvarez E (2009) Successful use of infliximab in a patient with neuro-Beh\u00e7et\u2019s disease. Int J Rheum Dis 12(3):264\u2013266","journal-title":"Int J Rheum Dis"},{"issue":"7","key":"4054_CR30","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s10067-011-1726-1","volume":"30","author":"A Borhani Haghighi","year":"2011","unstructured":"Borhani Haghighi A, Safari A, Nazarinia MA, Habibagahi Z, Shenavandeh S (2011) Infliximab for patients with neuro-Behcet\u2019s disease: case series and literature review. Clin Rheumatol 30(7):1007\u20131012","journal-title":"Clin Rheumatol"},{"issue":"5","key":"4054_CR31","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s00296-011-1915-x","volume":"32","author":"U Studer","year":"2012","unstructured":"Studer U, Ruehe B, Waldegg G, Vajtai I, Escher R, Aeberli D (2012) Atypical presentation of Beh\u00e7et\u2019s disease with central nervous system involvement successfully treated with infliximab. Rheumatol Int 32(5):1431\u20131435","journal-title":"Rheumatol Int"},{"issue":"8","key":"4054_CR32","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/1346-8138.12203","volume":"40","author":"H Kanemaru","year":"2013","unstructured":"Kanemaru H, Makino T, Jinnin M, Yonemitsu A, Makino K, Ihn H (2013) Case of neuro-Beh\u00e7et\u2019s disease successfully maintained a remission using infliximab for 2\u00a0years. J Dermatol 40(8):632\u2013634","journal-title":"J Dermatol"},{"issue":"1","key":"4054_CR33","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.jns.2014.09.052","volume":"347","author":"MD Filippo","year":"2014","unstructured":"Filippo MD, Gregorio MD, Nannini C, Gaetani L, Gallina C, Floridi P et al (2014) Infliximab monotherapy for neuro-Beh\u00e7et\u2019s disease: a case report. J Neurol Sci 347(1):389\u2013390","journal-title":"J Neurol Sci"},{"issue":"24","key":"4054_CR34","doi-asserted-by":"publisher","first-page":"e3863","DOI":"10.1097\/MD.0000000000003863","volume":"95","author":"T Hibi","year":"2016","unstructured":"Hibi T, Hirohata S, Kikuchi H, Tateishi U, Sato N, Ozaki K et al (2016) Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore) 95(24):e3863","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"4054_CR35","doi-asserted-by":"publisher","first-page":"e258","DOI":"10.1212\/NXI.0000000000000258","volume":"3","author":"B Zeydan","year":"2016","unstructured":"Zeydan B, Uygunoglu U, Saip S, Demirci ON, Seyahi E, Ugurlu S et al (2016) Infliximab is a plausible alternative for neurologic complications of Beh\u00e7et disease. Neurol Neuroimmunol Neuroinflammation 3(5):e258","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"1\u20132","key":"4054_CR36","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jns.2008.05.002","volume":"272","author":"H Kikuchi","year":"2008","unstructured":"Kikuchi H, Aramaki K, Hirohata S (2008) Effect of infliximab in progressive neuro-Beh\u00e7et\u2019s syndrome. J Neurol Sci 272(1\u20132):99\u2013105","journal-title":"J Neurol Sci"},{"issue":"1","key":"4054_CR37","first-page":"55","volume":"6","author":"A Jalili","year":"2009","unstructured":"Jalili A, Kinaciyan T, Barisani T, Peck-Radosavljevic M, Stingl G, Geusau A et al (2009) Successful treatment of refractory Beh\u00e7et\u2019s disease with the TNF-alpha blocker infliximab. Iran J Immunol IJI 6(1):55\u201358","journal-title":"Iran J Immunol IJI"},{"issue":"3","key":"4054_CR38","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1159\/000277928","volume":"220","author":"D Donghi","year":"2010","unstructured":"Donghi D, Mainetti C (2010) Infliximab for the treatment of refractory Adamantiades-Beh\u00e7et disease with articular, intestinal, cerebral and ocular involvement. Dermatol Basel Switz 220(3):282\u2013286","journal-title":"Dermatol Basel Switz"},{"key":"4054_CR39","doi-asserted-by":"publisher","first-page":"301","DOI":"10.2147\/IMCRJ.S117731","volume":"9","author":"H Karube","year":"2016","unstructured":"Karube H, Kamoi K, Ohno-Matsui K (2016) Anti-TNF therapy in the management of ocular attacks in an elderly patient with long-standing Beh\u00e7et\u2019s disease. Int Med Case Rep J 9:301\u2013304","journal-title":"Int Med Case Rep J"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-018-4054-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-018-4054-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-018-4054-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T19:09:23Z","timestamp":1558033763000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-018-4054-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,17]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["4054"],"URL":"https:\/\/doi.org\/10.1007\/s00296-018-4054-9","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"type":"print","value":"0172-8172"},{"type":"electronic","value":"1437-160X"}],"subject":[],"published":{"date-parts":[[2018,5,17]]},"assertion":[{"value":"20 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}